✦ LIBER ✦

[Advances in Pharmacology] Current State of Alzheimer's Disease Research and Therapeutics Volume 64 || Hsp90 Modulation for the Treatment of Alzheimer’s Disease

✍ Scribed by Zhao, Huiping

Book ID: 120322463
Publisher: Elsevier
Year: 2012
Tongue: English
Weight: 489 KB
Category: Article
ISBN: 0123948169
ISSN: 1054-3589
DOI: 10.1016/B978-0-12-394816-8.00001-5

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

[Advances in Pharmacology] Current State

[Advances in Pharmacology] Current State of Alzheimer's Disease Research and Therapeutics Volume 64 || Mitochondrial Abnormalities in Alzheimer’s Disease

✍ Silva, Diana F. 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 658 KB

[Advances in Pharmacology] Current State

[Advances in Pharmacology] Current State of Alzheimer's Disease Research and Therapeutics Volume 64 || scyllo-Inositol, Preclinical, and Clinical Data for Alzheimer’s Disease

✍ Ma, Keran 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 583 KB

[Advances in Pharmacology] Current State

[Advances in Pharmacology] Current State of Alzheimer's Disease Research and Therapeutics Volume 64 || Altering Mitochondrial Dysfunction as an Approach to Treating Alzheimer’s Disease

✍ Colca, Jerry R. 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 476 KB

[Advances in Pharmacology] Current State

[Advances in Pharmacology] Current State of Alzheimer's Disease Research and Therapeutics Volume 64 || Activation of Protein Kinase C Isozymes for the Treatment of Dementias

✍ Sun, Miao-Kun 📂 Article 📅 2012 🏛 Elsevier 🌐 English ⚖ 721 KB

Molecular and Cellular Therapeutics (Whi

Molecular and Cellular Therapeutics (Whitehouse/Molecular and Cellular Therapeutics) || Advances in the Treatment of Alzheimer's Disease

✍ Whitehouse, David; Rapley, Ralph 📂 Article 📅 2012 🏛 John Wiley & Sons, Ltd ⚖ 92 KB

Advances in the development of kinase in

Advances in the development of kinase inhibitor therapeutics for Alzheimer's disease

✍ Mary J. Savage; Diane E. Gingrich 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 576 KB

## Abstract Pharmaceutical approaches to slow the progression of Alzheimer's disease (AD) have focused primarily on reducing production or increasing clearance of amyloid β peptide (Aβ). Recent clinical trial results question the efficacy of targeting Aβ for treatment of mild to moderate AD, highli